αc helix displacement as a general approach for allosteric modulation of protein kinases

Drug Discovery Today

Volumn 18, Issue 7-8, 2013, Pages 407-414

  Palmieri, Lorenzo ^a   Rastelli, Giulio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE C;

ALLOSTERISM; ALPHA C HELIX; ALPHA HELIX; CRYSTAL STRUCTURE; HUMAN; PROTEIN CONFORMATION; REVIEW;

ALLOSTERIC REGULATION; BINDING SITES; DRUG DISCOVERY; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN STRUCTURE, SECONDARY;

EID: 84875747743     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.11.009     Document Type: Review

References (64)

1. G. Manning The protein kinase complement of the human genome Science 298 2002 1912 1934 (Pubitemid 35425239)
2. H.M. Berman The Protein Data Bank Nucleic Acids Res. 28 2000 235 242 (Pubitemid 30047768)
3. J. Dietrich The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796 Bioorg. Med. Chem. 18 2010 5738 5748
4. F. Zuccotto Through the "Gatekeeper Door": exploiting the active kinase conformation J. Med. Chem. 53 2010 2681 2694
5. J.S. Sebolt-Leopold Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat. Med. 5 1999 810 816 (Pubitemid 29318616)
6. S.F. Barnett Identification and characterization of pleckstrin-homology- domain-dependent and isoenzyme-specific Akt inhibitors Biochem. J. 385 2005 399 408 (Pubitemid 40165072)
7. J. Zhang Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463 2010 501 506
8. M. Rabiller Proteus in the world of proteins: conformational changes in protein kinases Arch. Pharm. 343 2010 193 206
9. V. Lamba, and I. Ghosh New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors Curr. Pharm. Des. 18 2012 2936 2945
10. N. Jura Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms Mol. Cell 42 2011 9 22
11. J. Eswaran, and S. Knapp Insights into protein kinase regulation and inhibition by large scale structural comparison Biochim. Biophys. Acta 1804 2010 429 432
12. R.A. Norman Structural approaches to obtain kinase selectivity Trends Pharmacol. Sci. 33 2012 273 278
13. A.P. Kornev Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc. Natl. Acad. Sci. U.S.A. 103 2006 17783 17788 (Pubitemid 44852237)
14. S.S. Taylor, and A.P. Kornev Protein kinases: evolution of dynamic regulatory proteins Trends Biochem. Sci. 36 2011 65 77
15. D.O. Morgan Principles of CDK regulation Nature 374 1995 131 134
16. X. Zhang An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125 2006 1137 1149 (Pubitemid 43866200)
17. P. Filippakopoulos Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation Cell 134 2008 793 803
18. L.R. Pearce The nuts and bolts of AGC protein kinases Nat. Rev. Mol. Cell Biol. 11 2010 9 22
19. B. Nagar Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase Mol. Cell 21 2006 787 798 (Pubitemid 43376129)
20. T.O. Fischmann Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors Biochemistry 48 2009 2661 2674
21. J.F. Ohren Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat. Struct. Mol. Biol. 11 2004 1192 1197
22. J.S. Warmus 2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4- oxadiazoles-O-alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase) Bioorg. Med. Chem. Lett. 18 2008 6171 6174
23. C. Iverson RDEA119/BAY 869766 a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer Cancer Res. 69 2009 6839 6847
24. H. Tecle Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK? Bioorg. Med. Chem. Lett. 19 2009 226 229
25. R.A. Heald Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions J. Med. Chem. 55 2012 4594 4604
26. C. Meier Engineering human MEK-1 for structural studies: a case study of combinatorial domain hunting J. Struct. Biol. 177 2012 329 334
27. K.K. Aertgeerts Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein J. Biol. Chem. 286 2011 18756 18765
28. E.R. Wood A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64 2004 6652 6659 (Pubitemid 39297926)
29. C. Qiu Mechanism of activation and inhibition of the HER4/ErbB4 kinase Structure 16 2008 460 467 (Pubitemid 351324111)
30. T. Ishikawa Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold J. Med. Chem. 54 2011 8030 8050
31. G.M. Higa, and J. Abraham Lapatinib in the treatment of breast cancer Expert Rev. Anticancer Ther. 7 2007 1183 1192 (Pubitemid 47521015)
32. N.D. D'Angelo Design, synthesis, and biological evaluation of potent c-Met inhibitors J. Med. Chem. 51 2008 5766 5779
33. M.H. Norman Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives J. Med. Chem. 55 2012 1858 1867
34. G. Bollag Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
35. F. Lovering Identification of type-II inhibitors using kinase structures Chem. Biol. Drug Des. 80 2012 657 664
36. J.M. Axten Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl} -2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) J. Med. Chem. 55 2012 7193 7207
37. C.K. Smith, and W.T. Windsor Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry Biochemistry 46 2007 1358 1367 (Pubitemid 46208483)
38. P. Rusconi RAS/RAF/MEK inhibitors in oncology Curr. Med. Chem. 19 2012 1164 1176
39. A. Balendran PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2 Curr. Biol. 9 1999 393 404 (Pubitemid 29205782)
40. J.A. Zorn, and J.A. Wells Turning enzymes ON with small molecules Nat. Chem. Biol. 6 2010 179 188
41. R.M. Biondi High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site EMBO J. 21 2002 4219 4228
42. V. Hindie Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1 Nat. Chem. Biol. 5 2009 758 764
43. A. Stroba 3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds J. Med. Chem. 52 2009 4683 4693
44. M. Engel Allosteric activation of the protein kinase PDK1 with low molecular weight compounds EMBO J. 25 2006 5469 5480 (Pubitemid 44847188)
45. J.D. Sadowsky Turning a protein kinase on or off from a single allosteric site via disulfide trapping Proc. Natl. Acad. Sci. U.S.A. 108 2011 6056 6061
46. E.V. Bobkova Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening J. Biol. Chem. 285 2010 18838 18846
47. L.A. Lopez-Garcia Allosteric regulation of protein kinase PKCζ by the N-terminal C1 domain and small compounds to the PIF-pocket Chem. Biol. 18 2011 1463 1473
48. W. Fröhner 4-Benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCζ J. Med. Chem. 54 2011 6714 6723
49. C.W. Lindsley Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors Bioorg. Med. Chem. Lett. 15 2005 761 764 (Pubitemid 40143162)
50. W.-I. Wu Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition PLoS ONE 5 2010 e12913
51. M.A. Ashwell Optimization of a series of 3-(3-Phenyl-3H-imidazo pyridin-2-yl) pyridin-2-amines: orally bioavailable, selective and potent ATP-independent Akt inhibitors J. Med. Chem. 55 2012 5291 5310
52. E.V. Schneider The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder J. Mol. Biol. 412 2011 251 266
53. A. Echalier Recent developments in cyclin-dependent kinase biochemical and structural studies Biochim. Biophys. Acta 1804 2010 511 519
54. S. Betzi Discovery of a potential allosteric ligand binding site in CDK2 ACS Chem. Biol. 6 2011 492 501
55. S. Baumli The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508 ACS Chem. Biol. 7 2012 811 816
56. E.R. Wood 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4- anilines as tunable covalent modifiers of ErbB kinases Proc. Natl. Acad. Sci. U.S.A. 105 2008 4 10
57. C.-H. Yun The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U.S.A. 105 2008 2070 2075 (Pubitemid 351439466)
58. N. Jura Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 Proc. Natl. Acad. Sci. U.S.A. 106 2009 21608 21613
59. F. Shi ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation Proc. Natl. Acad. Sci. U.S.A. 107 2010 7692 7697
60. J. Monsey Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system J. Biol. Chem. 285 2010 7035 7044
61. A. Dixit, and G.M. Verkhivker Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases PLoS Comput. Biol. 7 2011 e1002179
62. I. Buch Allosteric regulation of glycogen synthase kinase 3β: a theoretical study Biochemistry 49 2010 10890 10901
63. R. Bayliss Structural basis of Aurora-A activation by TPX2 at the mitotic spindle Mol. Cell 12 2003 851 862 (Pubitemid 37352779)
64. E.E. Thompson Comparative surface geometry of the protein kinase family Protein Sci. 18 2009 2016 2026